Another study (n = 609) reported that urine ctDNA biomarkers (TP53, RASSF1a, and GSTP1) combined with serum AFP significantly increased the sensitivity for early-stage HCC detection from 62 to 92% (BCLC stage 0, Kim et al. 2022a). This evidence concerns the gene TP53 and hepatocellular carcinoma.